

A. For Equity Issues

Sr No.	Name of the Issue:	Mahamaya Lifesciences Limited
1	Type of Issue (IPO/ FPO)	Initial Public Offering (IPO) on SME Platform of BSE India Limited ("BSE Source: Prospectus of the Company)
2	Issue size (Rs. Crore)	70.44
	Source: Prospectus of the Company	
3	Grade of issue alongwith name of the rating agency	As this is an issue consisting only of Equity Shares, there is no requirement to obtain credit rating for the Offer
	Source: Prospectus of the Company	
4	Subscription level (number of times). If the issue was undersubscribed, please clarify how the funds were arranged.	
	Source: Final post-issue report dated	NOVEMBER 21, 2025
		1.48

5	QIB holding (as a % of total outstanding capital) as disclosed to stock exchanges (See Regulation 31 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015	
	Particulars	%
	(i) allotment in the issue	11.06
	(ii) at the end of the 1st Quarter immediately after the listing of the issue (March 2026)	7.30
	(iii) at the end of 1st FY (as on year ended March 2026)	7.30
	(iv) at the end of 2nd FY (as on year ended March 2027)	NA
	(v) at the end of 3rd FY (as on year ended March 2028)	NA

Note:
 (1) Source: Basis of Allotment and Shareholding pattern as available on BSE
 (2) Total Outstanding Capital (no. of shares) is 2,34,05,000

6	Financials of the issuer (as per the annual financial results submitted to stock exchanges under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015			
	Parameters	1st FY (For the period ended March 31, 2026)	2nd FY (For the period ended March 31, 2027)*	3rd FY (For the period ended March 31, 2028)*
			Amount in Crores	
	Income from operations	328.873	Not Available	Not Available
	Net Profit for the period	16.52	Not Available	Not Available
	Paid-up equity share capital	23.41	Not Available	Not Available
	Reserves excluding revaluation reserves	98.625	Not Available	Not Available

Source: BSE Filing of financial Result

7	Trading status in the scrip of the issuer (whether frequently traded (as defined under Regulation 2 (j) of the SAST Regulations, 2011 or infrequently traded/ delisted/ suspended by any stock exchange, etc.)	
	Particulars	Status
	(i) at the end of 1st FY(March 31, 2026)	Active
	(ii) at the end of 2nd FY(March 31, 2027)*	NA*
	(iii) at the end of 3rd FY(March 31, 2028)*	NA*
	*Trading status not disclosed as the relevant fiscal year has not been completed	
	Source: NSE	

8	Change, if any, in directors of issuer from the disclosures in the offer document (See Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015)		
	Particulars	Name of the Director	Appointed / Resigned
	(i) at the end of 1st FY (March 31, 2026)	NA	NA
	(ii) at the end of 2nd FY (March 31, 2027)	NA	NA
	(iii) at the end of 3rd FY (March 31, 2028)	NA	NA

Source: MCA and BSE

9	Status of implementation of project/ commencement of commercial production (as submitted to stock exchanges under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015)	
	(i) Details of Estimated Schedule of Implementation of Projects forming part of the Objects of the Issue as per Prospectus	NA
	(ii) Actual implementation	NA
	(iii) Reasons for delay in implementation, if any	NA

10	Status of utilization of issue proceeds (as submitted to stock exchanges under Regulation 32 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015				
	Object	As disclosed in Offer Document	Actual Utilisation as on 31.03.2026	Total Unutilised Amount as on 31.03.2026	Reason for deviation, if any
	Purchase of Equipment for Fungicides, Insecticides and Bio Fermented formulations	2,975	0.415	2,561	
	Purchase of Equipment for herbicides	0,777	0.083	0,694	
	Funding of capital expenditure towards setting up of new technical setting up of new technical manufacturing plant	29,424	0.759	28,664	
	Construction of Warehouse and Purchase of machinery	2,525	1,652	0,874	
	Funding of Working Capital	18,00	18,00	0,00	
	General corporate purposes	8,262	8,262	0,00	
	Total	61,964	28,171	33,794	

Source: BSE

11	Comments of monitoring agency, if applicable (See Regulation 41 & 137 of ICDR Regulations, 2018 read with Regulation 32 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015	
	i. Comments on use of funds	Pursuant to a circular resolution passed by the Board of Directors on March 10, 2025, the Company has approved the rescheduling of utilisation of the unutilised IPO proceeds in subsequent fiscal years up to March 31, 2028 The Company has utilised the proceeds towards the object during the Period ended March 31, 2026
	ii. Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	There is no deviation
	iii. Any other reservations expressed by the monitoring agency about the end use of funds	Not Applicable
	(To be submitted till the time the issue proceeds have been fully utilized)	

12	Price-related data																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																		
----	--------------------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Source: NSE

Note: In case any of the above reporting dates happens to be a holiday, the immediately following working day may be taken

13	Basis for Issue Price and Comparison with Peer Group & Industry Average (Source of accounting ratios of peer group and industry average may be indicated; source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)						
	Accounting ratio	Name of company	At the end of 1st FY (31-03-2026)	At the end of 2nd FY (31-03-2027)	At the end of 3rd FY (31-03-2028)		
	EPS	Issuer: Mahamaya Lifesciences Limited	8.33	Not Available	Not Available		
		Peer: Nova Agritech Limited	0.59	Not Available	Not Available		
		Peer: Bhagradha Chemicals & Industries Limited	2.02	Not Available	Not Available		
		Industry Avg:					
	P/E	Issuer: Mahamaya Lifesciences Limited	19.20	Not Available	Not Available		
		Peer: Nova Agritech Limited	37.63	Not Available	Not Available		
		Peer: Bhagradha Chemicals & Industries Limited	96.44	Not Available	Not Available		
		Industry Avg:					
	RoNW	Issuer: Mahamaya Lifesciences Limited	13.55%	Not Available	Not Available		
		Peer: Nova Agritech Limited	2.20%	Not Available	Not Available		
		Peer: Bhagradha Chemicals & Industries Limited	3.63%	Not Available	Not Available		
		Industry Avg:					
	NAV per share based on balance sheet	Issuer: Mahamaya Lifesciences Limited	52.10	Not Available	Not Available		
		Peer: Nova Agritech Limited	19.39	Not Available	Not Available		
		Peer: Bhagradha Chemicals & Industries Limited	55.8	Not Available	Not Available		
		Industry Avg:					

Source: BSE and NSE Announcement

Note: Standalone Data is considered for all the companies

14 Any other material information NIL

Disclaimer:

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by Oneview Corporate Advisors Private Limited ("OCAR") arising out of the SEBI Circular No. CIR/MRD/1/2012 dated January 10, 2012. This information is gathered from the Prospectus of the issuer, as amended, and from the filings made by the issuer with the BSE Limited ("BSE") / the "Stock Exchange", as applicable, from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the issuer.

While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above